PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT — Stella

Home/Acute Myeloid Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Acute Myeloid Leukemia trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

Key details

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Enrollment target

~43 participants

Started

March 2023

Primary completion

July 2026

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.